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Herbal medicines containing emodin, widely used for the treatment of hepatitis in clinic,
have been reported with hepatotoxicity in individuals. A modest inflammatory stress
potentiating liver injury has been linked to the idiosyncratic drug-induced liver injury (IDILI).
In this study, we investigated the hypothesis that lipopolysaccharide (LPS) interacts with
emodin could synergize to cause liver injury in rats. Emodin (ranging from 20, 40, to
80 mg/kg), which is in the range of liver protection, was administered to rats, before LPS
(2.8 mg/kg) or saline vehicle treatment. The biochemical tests showed that non-toxic
dosage of LPS coupled with emodin caused significant increases of plasma ALT and AST
activities as compared to emodin alone treated groups (P< 0.05). In addition, with LPS or
emodin alone could not induce any changes in ALT and AST activity, as compared with
the control group (0.5% CMC-Na treatment). Meanwhile, the plasma proinflammatory
cytokines, TNF-a, IL-1b, and IL-6 increased significantly in the emodin/LPS groups
compared to either emodin groups or the LPS (P < 0.05). Histological analysis showed
that liver damage was only found in emodin/LPS cotreatmented rat livers samples.
These results indicate that non-toxic dosage of LPS potentiates the hepatotoxicity
of emodin. This discovery raises the possibility that emodin and herbal medicines
containing it may induce liver injury in the inflammatory stress even in their therapeutic
dosages.
Keywords: emodin, lipopolysaccharide, idiosyncratic drug-induced liver injury, hepatotoxicity, proinflammatory
mediators, therapeutic dosages
INTRODUCTION
Liver injury is a fundamental pathological process in most hepatic diseases. Chronic liver injury
leads to hepatic fibrosis, liver cirrhosis, and even liver cancer (Beyoğlu and Idle, 2013; Huang et al.,
2013). Accordingly, many studies have been focused on the protective effects of natural compounds
or plant extracts upon various liver injury in vivo (Harnack et al., 2001; Bent and Ko, 2004). As
penetration and usage increase, consecutive reports of hepatotoxic effects have appeared gradually,
such as Shou-Wu Pian, Capsule Shengjing, and some herbs containing anthraquinones including
Polygonum multiflorum, Sennae fructus angustifoliae, and Rheum palmatum L. (Panis et al., 2005;
Stickel et al., 2005; Wang et al., 2011; Ma et al., 2015).
Emodin (1,3,8-trihydroxy-6-methyl anthraquinone) is an anthraquinone derivative from
Chinese herbs Rheum palmatum (rhubarb), Polygonum multiflorum, Cassia obtusifolia, etc.
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The hepatoprotective effects of emodin have been reported in
a series of studies using animal models (Zhang, 2006; Dong
et al., 2009; Bhadauria, 2010), and some Chinese medicine
compound prescriptions mainly containing rhubarb are often
used for the treatment of hepatitis in clinic (Liang et al.,
2006; Wang et al., 2010). However, recently, some studies have
reported a contradictory event that emodin has hepatotoxicity
to normal rats (National Toxicology Program, 2001; Wang et al.,
2009). Whereas the mechanism of emodin-induced liver injuries
remains to be elucidated and the risk factors of hepatotoxicity
are not well-defined, a research to investigate the paradoxical
effects of hepatoprotection and hepatotoxicity of emodin is
necessary.
Lipopolysaccharide (LPS) is the major component of the
outer membrane of Gram-negative bacteria. LPS, as a potent
inflammagen, could stimulate the immune system, which
subsequently releases numerous proinflammatory mediators
including cytokines [e.g., tumor necrosis factor-alpha (TNF-
a), interleukin-1b (IL-1b), interleukin-6 (IL-6), and other
chemokines], lipid metabolites, reactive oxygen species (ROS),
etc. In the past years, considerable experiments support that
human idiosyncratic drug-induced liver injury (IDILI) can be
reproduced in animals by concurrent exposure to low dose of LPS,
which induces a modest inflammatory stress (Ganey et al., 2004;
Roth and Ganey, 2011). Recent evidences from animal models
indicate that a mild inflammatory microenvironment, caused by
drug (such as trovafloxacin or chlorpromazine) treatment, may
enhances the susceptibility to hepatotoxic damage and thereby
result in a toxic effect (i.e., an “idiosyncratic” response; Barton
et al., 2001; Waring et al., 2006; Deng et al., 2009). These studies
suggest that emodin-induced liver injury in rats would synergize
to cause hepatotoxicity upon co-treatment with a non-toxic
but modestly inflammatory dose of LPS, namely, idiosyncratic
emodin-induced liver injury.
In this study, LPS-stimulated rats were used as a tool to
test this hypothesis by investigating the paradoxical effects of
hepatoprotective or hepatotoxic activity of emodin at the dosage
of hepatoprotection. Our data will not only offer significant
reference for the study of susceptible hepatotoxicity and rational
to use of emodin, but provide novel insight into the mechanisms
of emodin in liver protection.
MATERIALS AND METHODS
Reagents
Lipopolysaccharide derived from Escherichia coli serotype
055:B5 was used (Sigma-Aldrich, Inc., USA). Emodin and
sodium pentobarbital were purchased from the Sigma-Aldrich
(St. Louis, USA). Carboxymethylcellulose sodium (CMC-Na)
and formaldehyde were supplied by the Xilong Chemical
Co., Ltd. (Guangdong, China). The disposable vacuum blood
vessels and collection needles were purchased from the Tianjin
Hanaco Medical Materials Co., Ltd. (Tianjin, China). Alanine
transaminase (ALT), aspartate aminotransferase (AST) activity
and total bile acid (TBA) kits were purchased from the Jiancheng
bioengineering institute (Nanjing, China). Tumor necrosis
factor-a (TNF-a), interleukin-1b (IL-1b) and interleukin-6 (IL-6)
ELISA kits were purchased from the Dakewe for Biological
Technology Co., Ltd. (Beijing, China).
Animals and Treatments
All studies in vivo were conducted in the Laboratory Animal
Center of the 302 Military Hospital. Experimental rats are
maintained in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals, and
experimental procedures were approved by the Committee on
the Ethics of Animal Experiments of the 302 Military Hospital
(Approval ID: 11- 037). Male Sprague-Dawley (SD) rats weighing
180 to 200 g were used for these studies. Animals were allowed
to standard chow and water ad libitum under standard husbandry
conditions (22+ 2°C temperature, 60–80% relative humidity and
12 h photoperiod). They were allowed to acclimate for 1 week in
a 12 h light/dark cycle with lights turned on at 9:00 am.
The experimental animals are clustered into 4 groups: control
group (0.5%CMC-Na treatment), LPS group (2.8mg/kg), emodin
groups (20, 40, and 80 mg/kg, respectively), LPS/emodin groups
(2.8/20 mg/kg, 2.8/40 mg/kg, and 2.8/80 mg/kg, respectively).
The doses of LPS and emodin were used in a condition that
drug treatment did not cause a significant injury for rats. Rats
were fasted for 12 h only with water ad libitum, then received
intragastric administration of 0.5% CMC-Na mixture only as
control and 20, 40, and 80mg/kg emodin (dissolved in 0.5%CMC-
Na) for groups of emodin, LPS/emodin treatments. 3 h later, rats
were given 2.8 mg/kg LPS solution for experimental groups (LPS,
LPS/emodin) by tail injection. 7 h later, rats were anesthetized
with sodium pentobarbital (70 mg/kg i.p.), and plasma were
collected with a syringe containing sodium citrate by drawing
blood from the vena cava, then euthanized. Plasma was stored
at  20°C for further analysis and representative slices (1 cm) of
the ventral portion of the left lateral liver lobe was fixed in 10%
neutral buffered formalin for subsequent liver biochemical tests
and histological assessment of hepatic pathology.
Plasma Indicators and Histopathology
Assessment
Hepatic parenchymal cell injury was estimated by evaluating
plasma ALT, AST activity and TBA content using the Hitachi
clinical analyzer 7020 (Hitachi High-Technologies Co., Japan).
Inflammatory microenvironment was assessed by measuring
plasma TNF-a, IL-1b, and IL-6 contents using ELISA kits
according to the manufacturer’s protocol. Formalin fixed liver
samples were routinely processed and embedded in paraffin,
sectioned to a thickness of approximately 5 mm, and stained with
hematoxylin and eosin (HE).
Statistical Analysis
All the data presented in the manuscripts were analyzed using
the Statistical Package for the Social Sciences ofWindows, version
17.0 (SPSS Inc., Chicago, IL, USA). The inter-group variation was
measured by one-way analysis of variance (ANOVA). Difference
was considered statistically significant when P  0.05, and very
significant when P  0.01. The error bars represents the “SD”
value (standard deviation).
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FIGURE 1 | The Plasma biochemical indicators in the absence and presence of LPS with emodin. Rats were treated with various doses of emodin (20, 40,
or 80 mg/kg, i.g.) or its vehicle (0.5% CMC-Na). After 3 h, LPS or emodin/LPS groups animals received LPS (2.8 mg/kg, i.v.) or its vehicle (0.5% CMC-Na). (A) and
(B) Blood samples were taken at 7 h after the administration of LPS, and plasma ALT and AST levels were measured. (C) Plasma TBA content were measured from
the same conditions. The results were presented as mean  SD from of 10 rats. Significance of differences was from the value of emodin/LPS rats (*P < 0.05,
**P < 0.01 vs emodin groups). For groups, “+” and “ ” represent “presence” and “absence,” respectively.
FIGURE 2 | Chemokine and cytokine expression in rats cotreated with LPS and emodin. Rats were treated with emodin (20, 40, or 80 mg/kg, i.g.) or its
vehicle (0.5% CMC-Na) and LPS (2.8 mg/kg, i.v.) or its vehicle (0.5% CMC-Na) as described in Figure 1. (A–C) Showed Plasma proinflammatory cytokine levels
determined by ELISA for IL-1b, IL-6, and TNF-a respectively. The data were presented as mean  SD of 10 rats, and statistically significant difference (*P < 0.05, vs
emodin groups;P < 0.05, vs LPS group; #P < 0.05 and ##P < 0.01, vs control).
RESULTS
Common Changes in Rats
After observing and recording the external manifestations of rats,
they were administered by intragastric administration of emodin
or tail intravenously LPS. In control group, rats with smooth body
hair, urine, and spirit are normal as before. In emodin only groups,
rats with loose stools, soft stool, messy body hair, yellow urine are
appeared. In LPS/emodin groups, the activity of rats are becoming
significantly slow, sluggish, listlessness, except for loose stools,
messy body hair, and yellow urine, especially in the LPS/emodin
(2.8/80 mg/kg), whose phenomenon was more obvious even with
animal death.
Plasma Biochemical Index
Treatment of rats with emodin or LPS alone did not cause an
increase in plasmaALT, AST activity and TBA content, (Figure 1).
However, rats had significant increase in plasma ALT and AST
activities after co-treatment with 20, 40, or 80 mg/kg emodin plus
LPS as well as in TBA content with 80 mg/kg emodin plus LPS,
compared with emodin groups. The phenomenon indicates that
emodin or LPS alone did not induce liver injury in rats at any




Lipopolysaccharide challenge caused marked increases in the
levels of the proinflammatory cytokines TNF-a, IL-1b, and IL-
6 (P < 0.01 or P < 0.05) when compared with saline-treated
controls (Figure 2). Although trace amounts of LPS could
cause mild inflammation in rats, the HE staining from the
liver sections showed that those LPS alone injected rats do not
develop obvious hepatocellular injury (Figure 3). Furthermore,
the plasma proinflammatory cytokines levels are significantly
higher in the emodin/LPS groups comparing to either emodin
groups or LPS group (P < 0.05). The results demonstrated that
non-toxic dosage of LPS potentiated the hepatic inflammation in
the hepatoprotective doses of emodin.
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FIGURE 3 | Histopathological damage in rats liver given LPS, emodin only and cotreated with LPS/emodin. (A) Liver sections from rats were treated with
vehicle (0.5% CMC-Na); (B) with LPS (2.8 mg/kg); (C) emodin (20 mg/kg); (D) emodin (40 mg/kg); (E) emodin (80 mg/kg); (F) LPS/emodin (20 mg/kg); (G)
LPS/emodin (40 mg/kg); (H) LPS/emodin (80 mg/kg). Liver samples were collected at 7 h after LPS tail intravenously injection (HE stained,  200 magnification) and
HE staining was performed to investigate the histological changes in all experimental groups.
Liver Histopathology Assessment
Shown in Figure 3, no significantly histologic lesions were
observed in both control and emodin groups, since no obvious
histological lesion emerged. The hepatic lobule was clear, liver
cells were uniform, the nucleus was clearly visible, and liver
cells surrounding the central veins were distributed in radial
arrangement of liver cell cords. LPS-treated groups showed
evidences of mild pathological alteration: slight inflammatory
cells invasion in portal area around the blood vessels, a small
amount of kupffer cell proliferation and enlargement, which
showed inflammatory signaling pathways were activated.
However, there were significantly pathological changes in
LPS/emodin groups: hepatic blood sinus congestion expanded
obviously near the central vein, part of the liver cell visible
swelling, some cells have no nuclei even dot necrosis, and
a large number of inflammatory cells infiltration in portal
area around the blood vessels. In figure H, liver cell injury
increased significantly and randomly distributed, as well as
local necrosis of liver cells existed, which was not observed
in any of the livers from rats treated with LPS or emodin
alone.
DISCUSSION
In current studies, in order to investigate the hepatotoxicity
induced by the anthraquinone derivative emodin, we applied a
rat model of drug-inflammation interaction. Our data indicates
that emodin or LPS alone did not increase the clinical chemical
biomarkers of liver injury or cause any lesions in the liver.
However, in emodin/LPS-co-treated rats, serum markers of
hepatocellular injury were increased significantly, and foci of
necrotic parenchymal cells were found in livers. In clinic,
Chinese patent medicine containing emodin are proved with
a hepatoprotection role (Fang et al., 2011). Previous studies
have shown that animals treated with clinical equivalent dose of
emodin do not develop liver injury, while high dose and long
term treatment could induce hepatotoxicity (Zeng et al., 2013).
In Table 1, the data revealed that the hepatotoxic dose of emodin
wasmuch higher than the hepatoprotective dose of that in animals
(Zhan et al., 2000; Dang et al., 2008; Lei et al., 2008; Wang et al.,
2009; Zhao et al., 2009). Wang et al. (2009) treated rats for 3 weeks
with rhubarb with a dose of 3 g/kg (equivalent to emodin with
the dose of 45 mg/kg) and observed liver injuries. It is highly
possible that accumulative dose (around 945 mg/kg) could be
danger to the rat liver cells since livers are the major organs for the
drug metabolism. However, in our experiment, emodin coupled
with LPS could induce liver injury even in their therapeutic
doses (20, 40, and 80 mg/kg), accompanied by the immune
cell infiltration to the livers. This data is interesting since LPS-
mediated immune system activation promotes the liver injury.
In this way, the hepatotoxic effect of emodin treatment maybe
a hidden danger to patients with IDILI. Potentially, our research
helps to distinguish drugs, which is in the same pharmacologic
class but has idiosyncratic toxicity, to avoid adverse drug reactions
greatly.
Idiosyncratic adverse drug response is a type of adverse reaction
that occurs in a minority of patients during drug therapy.
Liver is one of the major organ targets (Roth and Ganey,
2011). Emodin with hepatic protective effect, is reported of
hepatotoxic effects in some cases. We suspected that it might
be associated with hepatic idiosyncratic adverse drug reactions
(IADRs), due to no significant correlation between age, gender,
dose and adverse reactions of some herbs containing it in clinic.
However, the mechanism of emodin-induced liver injury has
not been clarified because of the lack of experimental animal
models. Previous study has been proposed that inflammatory
stress may render an individual susceptible to IADRs, and
numerous IDILI have been developed in LPS/drug models that
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TABLE 1 | The hepatoprotection and hepatotoxicity of emodin in animals.
Administration
Drug Species Dosage Period Effect Reference
Emodin Rat 20 mg/kg 12 week Protective Dong et al., 2009
Emodin Rat 40 mg/kg 36 h Protective Zhao et al., 2009
Emodin Rat 40 mg/kg 12 week Protective Dang et al., 2008
Emodin Rat 20,40, 80 mg/kg 6 week Protective Zhan et al., 2000
Emodin Rat 406 mg/kg 1 times Toxic Lei et al., 2008
Mouse 580 mg/kg
Emodin Rat 340 mg/kg 14 week Toxic National Toxicology Program, 2001
Mouse 800 mg/kg
Rhubarb Rat a38, 76 g/kg 4 week Toxic Ma, 2007
Rhubarb Rat b14.7, 40 g/kg 4 week Toxic Wang et al., 2010
Rhubarb Rat c20 g/kg 3 week Toxic Wang et al., 2009
The total content of emodin generally presents 1.53% in rhubarb and was calculated according to its content of 1.5%; a38 and 76 g/kg Rhubarb were amounted to 570 and 1140mg/kg
of emodin; b14.7 and 40 g/kg Rhubarb is the equal of 220 and 600 mg emodin; c20 g/kg Rhubarb equals 300 mg/kg emodin.
support the inflammatory stress hypothesis. LPS binds to Toll-
like receptors (TLRs), which is primary signaling receptors for
LPS, initiates immune activating signals and leads to stimulation
of inflammatory cells and consequent expression and release of
numerous proinflammatory mediators (Testro and Visvanathan,
2009; Guo and Friedman, 2010). These mediators, including
cytokines (TNF-a, IL-1b, IL-6, etc.), toxic proteases, ROS, might
increase liver cell sensitivity to drugs when the response is modest
or lead to liver injury in aggravated conditions (Gandhi et al.,
2013). In addition, clinical chemistry (especially liver enzymes
ALT and AST) and histopathology data are hallmark indicators
of hepatotoxicity in animal models (Zou, 2010). We evaluated
the utility of LPS/drug models in terms of cytokines, clinical
chemistry and histopathology to explore mechanisms of emodin-
induced liver injury. When given alone, none of the doses of
emodin tested (20–80 mg/kg) produced significant increases in
serum cytokines such as TNF-a, IL-1b and IL-6. However, when
coadministered with non-injurious LPS which induces modest
inflammation, cytokine levels are significantly enhanced at the
emodin dose of 20 mg/kg and greater. Neither emodin nor LPS
given alone had a significant hepatotoxic effect as measured by
ALT and AST activity compared to control animals. In contrast,
co-treatment of rats with emodin/LPS led to a significant increase
in liver injury markers expressions (ALT, AST, and TBA). The
results might indicate proinflammatory episode increased liver
cell sensitivity, which transformed therapeutic dosages of emodin
into toxic doses and led to liver injury. Other drugs associatedwith
idiosyncratic hepatotoxicity in humans, such as ranitidine and
trovafloxacin, also had a synergistic effect on the LPS-mediated
models similarly.
Glycyrrhiza, possessing several pharmacological activities
including anti-inflammatory and hepatoprotective, has been
used as herbal medicine worldwide for over 4000 years (Shibata,
2000; Yoshida et al., 2007). As the main active ingredient of
Glycyrrhiza, glycyrrhizin is reported to suppress the LPS sensor
toll-like receptor 4 (TLR4)/Myeloid differentiation protein 2
(MD-2) complex signaling, result in attenuating LPS-mediated
inflammatory response (Kim et al., 2008; Schrofelbauer et al.,
2009; Honda et al., 2012). According to traditional Chinese
Medicine (TCM) theories, compatibility of medicines are usually
used to reach the goal of better curative efficacies and fewer side
effects, just like Rhubarb and Glycyrrhiza were used together
in one prescription (Cao and Wang, 2013). Typically, “Rhubarb
Glycyrrhiza Soup,” from the ancient medical book Synopsis of
Golden Chamber written by the medical sage Zhang Zhongjing,
is a classic clinical decoction, which has powerful curative effects
in treating diabetes, severe acute pancreatitis, detoxification,
liver and renal injury, and is widely used till now (Han et al.,
2010). Most TCM practitioners in modern times commonly
believe that Glycyrrhiza may harmonize and modify Rhubarb
(Shen et al., 2013). We predict that glycyrrhizin of Glycyrrhiza
can regulate TLR4 signaling path, decrease production of
proinflammatory cytokines to alleviate the idiosyncratic liver
injury of emodin absorbed into bloodstream, which maybe
a most likely hypothesis giving a new approach for future
researches.
CONCLUSION
In summary, inflammation response could decrease the
threshold for toxicity, making an individual more susceptible
to some idiosyncratic hepatotoxicants. In this study, a modest
inflammatory episode induced by non-injurious LPS as the
idiosyncratic liver injury model potentiates emodin-induced liver
injury in rats, whereas neither LPS nor emodin was hepatotoxic
alone. Although the mechanisms underlying these are not yet
fully understood, the finding raise the possibility that patients
experiencing an inflammatory response who concurrently
consume alternative medicines containing emodin maybe
susceptible to liver injury.
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